==> selects oral bioavailable

==> increases efficacy of clinical trials

==> results
directly available

Only compound structure needed
==> no further assays, synthesis
 or costs


The largest  knowledge base
on bioavailability worldwide.

An expert system for finding
drug candidates.


 An expert system for finding molecules with antibiotic activity.

 An expert system for finding molecules with antiviral activity.

Recent collaborations:

The expert systems of PharmaInformatic are used world-wide. Here are some testimonials from our clients.


Collaboration with Avivia BV

Avivia BV and PharmaInformatic have entered into a research collaboration agreement. Under the terms of the agreement, PharmaInformatic has estimated human oral bioavailability of prodrugs for the treatment of cancer.

We used the Impact-F system to assess the oral bioavailability of two different prodrugs of the same drug that we had in development. We did not have the resources to investigate the oral bioavailability of both with the traditional approach in animals (labelling the mand full pharmacokinetics). The Impact-F analyzed our molecules and it found out that chemically speaking it was very comparable to some other prodrugs and drugs from which oral bioavailability data was available and we used this to make a selection.

This lead candidate is now in clinical development.

In conclusion, we were quite impressed with the Impact-F system and it really helped us to better understand our prodrugs without too many animal experiments.

Hans Platteeuw, Chief Executive Officer at Avivia BV


Collaboration with UNIZYME Laboratories A/S

PharmaInformatic and UNIZYME Laboratories A/S have entered into a research collaboration for the development of new therapeutic agents for the treatment of inflammatory diseases. The research collaboration is initiated and supported by the European Union IN2LifeSciences project and by the Interreg IVB North-West Europe programme. PharmaInformatic uses the expert system IMPACT-F to prioritise dipeptidyl peptidase I inhibitors (DPPI, cathepsin C) based on their estimated oral bioavailability in humans.

Dipeptidyl peptidase I is a therapeutic drug target for the treatment of a number of inflammatory and autoimmune diseases. Cathepsin C inhibitors could potentially be effective therapeutics for the treatment of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, sepsis, rheumatoid arthritis, psoriasis, myocardial infarction, inflammatory bowel disease and multiple sclerosis.

Collaboration with Bridge Bioresearch PLC

PharmaInformatic and BRIDGE BIORESEARCH PLC have signed a collaboration agreement. Under this agreement PharmaInformatic applies the expert system IMPACT-F in order to predict the oral bioavailability of drug candidates for the treatment of type 2 diabetes.

Søren Stenderup explains the collaboration in the newsletter from BioPeople, Denmark:

"We are developing a molecule for the treatment of Type II diabetes and had all documentation ready except for data on the bioavailability in humans. We were approached by the German biotech company Pharmainformatic which has an  expert system called IMPACT-F that predicts the oral bioavailability of novel drugs in humans. We agreed with Pharmainformatic to apply for an innovation voucher to finance the test of our drug and in short time our development project was taken to the next step."

Søren Stenderup, CEO at Bridge Bioresearch

Diabetes mellitus type 2 is a metabolic disorder which affects a large number of people. According to the World Health Organisation, about 347 million people suffer from diabetes worldwide. About 90% of them suffer from diabetes type 2.

Oral bioavailability is a key property in drug design and development. The expert system IMPACT-F estimates oral bioavailability of future drug candidates in humans.

The calculation is based on reliable computational models, which have been derived from the largest knowledge base on bioavailability worldwide (PACT-F).


Several research collaborations are supported by the European Union IN2LifeSciences project and by the Interreg IVB North-West Europe programme. IN2LifeSciences supports SME with the development or commercialisation of their innovations. PharmaInformatic is a technology provider within the IN2LifeScience program. For further information: IN2LifeScience-website.



Frequently Asked Questions (FAQ):

Is IMPACT-F restricted to a specific therapeutic area, such as antibacterials or cancer?

What is required to predict oral bioavailability with IMPACT-F?

Looking for similar drug structures and bioavailability data related to your research project?

Bioavailability data from similar compounds to a specific drug-candidate are very difficult to find in the literature. Without using a structure based knowledge base it is almost impossible.

PACT-F can help to identify the most similar drugs which have been previously investigated in preclinical and clinical trials. Contact us for more information.




© Copyright 2004-2017 PharmaInformatic Boomgaarden. All rights reserved.         Site map         Contact         Terms of Use         Imprint        

efficiency of drugs
advanced clinical trials:

Follow us on Twitter, connect via LinkedIn: